Companies aTYR Pharma
aTYR Pharma (ATYR): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me aTYR Pharma’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,300,525FY2023
- $1,480,522FY2024
- $3,456,253FY2025
CEO total pay was $3,456,253 in fiscal 2025, up from $1,480,522 in fiscal 2024.
FY2025: salary $638,977 · bonus $0 · stock awards $0 · option awards $2,595,200
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sanjay Shukla | $638,977 | $0 | $0 | $2,595,200 | $210,862 | $0 | $11,214 | $3,456,253 |
| President and CEO | ||||||||
| Jill Broadfoot | 471,790 | 0 | 0 | 713,680 | 113,229 | 0 | 11,214 | 1,309,913 |
| Chief Financial Officer | ||||||||
| Nancy Denyes | 451,570 | 0 | 0 | 713,680 | 108,377 | 0 | 11,214 | 1,284,841 |
| General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Sanjay Shukla | $3,456,253 | $1,480,522 | $1,300,525 | ↑ +1,975,731 |
| Jill Broadfoot | 1,309,913 | 746,163 | 677,837 | ↑ +563,750 |
| Nancy Denyes | 1,284,841 | 729,305 | 651,283 | ↑ +555,536 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's executive compensation philosophy is based on aligning executive interests with stockholder interests through long-term incentives linked to Company performance, attracting and retaining superior executive talent, and providing incentives that reward the achievement of performance goals that directly correlate to the enhancement of stockholder value.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford (part of the Rewards Solutions practice at Aon plc) |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jill Broadfoot | Option | — | — | — | — | — | $713,680 |
| Sanjay Shukla | Option | — | — | — | — | — | 2,595,200 |
| Nancy Denyes | Option | — | — | — | — | — | 713,680 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jill Broadfoot | $0 | $0 | $713,680 | 0.0% |
| Sanjay Shukla | 0 | 0 | 2,595,200 | 0.0% |
| Nancy Denyes | 0 | 0 | 713,680 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Nancy Denyes | Option | 896 | 5.52 | — |
| Jill Broadfoot | Option | 1,250 | 5.52 | — |
| Nancy Denyes | RSU | 2,687 | — | 2,104 |
| Sanjay Shukla | Option | 3,458 | 5.52 | — |
| Jill Broadfoot | RSU | 3,750 | — | 2,937 |
| Jill Broadfoot | Option | 7,849 | 2.81 | — |
| Nancy Denyes | Option | 9,177 | 2.81 | — |
| Sanjay Shukla | RSU | 10,375 | — | 8,125 |
| Jill Broadfoot | Option | 24,507 | 2.2 | — |
| Nancy Denyes | Option | 24,507 | 2.2 | — |
| Sanjay Shukla | Option | 53,779 | 2.81 | — |
| Jill Broadfoot | Option | 78,125 | 1.5 | — |
| Nancy Denyes | Option | 78,125 | 1.5 | — |
| Sanjay Shukla | Option | 98,028 | 2.2 | — |
| Jill Broadfoot | Option | 211,980 | 3.74 | — |
| Nancy Denyes | Option | 211,980 | 3.74 | — |
| Sanjay Shukla | Option | 312,500 | 1.5 | — |
| Sanjay Shukla | Option | 770,834 | 3.74 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Timothy P. CoughlinIndependent · Board Chair · Audit | $82,200 | $0 | $112,085 | — | $0 | $194,285 |
| Svetlana Lucas, Ph.DIndependent · Audit (Chair) · Partial-year service | 63,044 | 0 | 112,085 | — | 0 | 175,129 |
| Jane A. Gross, Ph.DIndependent · Compensation · Partial-year service | 58,338 | 0 | 112,085 | — | 0 | 170,423 |
| Sara L. Zaknoen, M.DIndependent · Compensation · Partial-year service | 55,337 | 0 | 112,085 | — | 0 | 167,422 |
| Eric BenevichIndependent · Audit · Compensation | 51,764 | 0 | 112,085 | — | 0 | 163,849 |
| Paul Schimmel, Ph.DIndependent | 40,000 | 0 | 112,085 | — | 0 | 152,085 |
| John K. ClarkeIndependent · Not standing for re-election · Departed during FY | 19,775 | 0 | 0 | — | 0 | 19,775 |
| Sanjay S. Shukla, M.D., M.SEmployee director · Partial-year service | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $370,458 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $370,458 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names aTYR Pharma as a peer
Companies that benchmark against ATYR
5 companies name ATYR as a compensation peer
The list of companies that name ATYR as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies aTYR Pharma names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Scholar Rock Holding Corporation | 2025 | David Hallal | $637,500 | $22,518,500 | $7,624,988 | $452,293 | $33,300,927 |
| 2 | Altimmune, Inc. | 2025 | Vipin Garg | 658,694 | 1,153,600 | 4,812,167 | 357,753 | 8,026,590 |
| 3 | Allakos Inc. | 2023 | Robert Alexander | 805,460 | 2,171,340 | 2,623,519 | 684,641 | 6,299,426 |
| 4 | Pliant Therapeutics, Inc. | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 5 | KalVista Pharmaceuticals, Inc. | 2025 | Benjamin Palleiko | 477,202 | 3,731,160 | 0 | 0 | 5,094,999 |
| 6 | Savara Inc. | 2025 | Matthew Pauls | 660,000 | 3,870,000 | 0 | 297,000 | 4,845,000 |
| 7 | Trevi Therapeutics, Inc. | 2025 | Jennifer Good | 622,382 | 0 | 2,968,260 | 0 | 3,944,892 |
| 8 | aTYR Pharma | 2025 | Sanjay Shukla | 638,977 | 0 | 2,595,200 | 210,862 | 3,456,253 |
| 9 | Jasper Therapeutics, Inc. | 2024 | Ronald Martell | 727,272 | 438,000 | 1,740,640 | 309,091 | 3,215,003 |
| 10 | X4 Pharmaceuticals, Inc. | 2025 | Paula Ragan | 420,170 | 1,081,575 | 0 | 0 | 2,640,569 |
| 11 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 12 | Longboard Pharmaceuticals, Inc. | 2023 | Kevin Lind | 610,000 | 0 | 986,934 | 442,860 | 2,053,804 |
| 13 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 14 | Kezar Life Sciences, Inc. | 2024 | Christopher Kirk | 600,000 | 0 | 0 | 313,500 | 927,300 |
| — | Immunic, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Acelyrin, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Fortress Biotech, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| aTYR Pharma | 60% (Committee lowered payout from 75% achievement to 60% given EFZO-FIT study results)% | Option 100 | not disclosed | Radford (part of the Rewards Solutions practice at Aon plc) |
| Acelyrin, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allakos Inc. | not disclosed | Options 55 · RSU 45 | No | Compensia |
| Altimmune, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Fortress Biotech, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| Immunic, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Jasper Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| KalVista Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| Kezar Life Sciences, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Longboard Pharmaceuticals, Inc. | not disclosed | Option 100 | not disclosed | Frederic W. Cook & Co. |
| Pliant Therapeutics, Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Pearl Meyer; Alpine Rewards |
| Savara Inc. | 90% | RSU 100 | not disclosed | Aon |
| Scholar Rock Holding Corporation | not disclosed | not disclosed | No | Pay Governance |
| Trevi Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| X4 Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-05-01 | 55,237,719 | 1,353,536 | 256,535 | 97.61% | Passed |
| 2024 | 2024-05-22 | 42,468,397 | 397,926 | 50,833 | 99.07% | Passed |
| 2023 | 2023-05-17 | 37,246,069 | 1,007,212 | 45,497 | 97.37% | Passed |
| 2022 | 2022-04-26 | 18,771,202 | 51,254 | 32,563 | 99.73% | Passed |
| 2021 | 2021-04-28 | 7,519,078 | 136,228 | 18,011 | 98.22% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-05-01 | 97.61%a |
| 2024 | 2024-05-22 | 99.07%b |
| 2023 | 2023-05-17 | 97.37%c |
a. Approved under the standard stated in the filing — “Broker non-votes and abstentions will not be counted as votes properly cast with respect to such matter, and will have no effect on the proposal.”.
b. Approved under the standard stated in the filing — “Broker non-votes and abstentions will not be counted as votes properly cast with respect to such matter, and will have no effect on the proposal.”.
c. Approved under the standard stated in the filing — “Broker non-votes and abstentions will not be counted as votes properly cast with respect to such matter, and will have no effect on the proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Paul Schimmel | Director | 2026-05-11 | A | 50,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Svetlana Lucas | Director | 2026-05-11 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jane A. Gross | Director | 2026-05-11 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Benevich | Director | 2026-05-11 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy P. Coughlin | Director | 2026-05-11 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sara Zaknoen | Director | 2026-05-11 | A | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Schimmel | Director | 2026-05-27 | A | 100,000 | 0 | 49,630 | Common | Form 4 ↗ |
| Brandon Yaras | Chief Financial Officer | 2026-10-01 | A | 410,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (45 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Sanjay Shukla. DEF 14A, filed 2026-03-26. Section “Executive Compensation” · page 31. As printed: 3,456,253. View filing ↗
- Section 01, Jill Broadfoot. DEF 14A, filed 2026-03-26. Section “Executive Compensation”. As printed: 1,309,913. View filing ↗
- Section 01, Nancy Denyes. DEF 14A, filed 2026-03-26. Section “Executive Compensation”. As printed: 1,284,841. View filing ↗
- Section 03, Jill Broadfoot Option. DEF 14A, filed 2026-03-26. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Sanjay Shukla Option. DEF 14A, filed 2026-03-26. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 03, Nancy Denyes Option. DEF 14A, filed 2026-03-26. Section “SUMMARY COMPENSATION TABLE” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-03-26. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Timothy P. Coughlin. DEF 14A, filed 2026-03-26. Section “Director Compensation”. As printed: 194,285. View filing ↗
- Section 08, Svetlana Lucas, Ph.D. DEF 14A, filed 2026-03-26. Section “Director Compensation”. As printed: 175,129. View filing ↗
- Section 08, Jane A. Gross, Ph.D. DEF 14A, filed 2026-03-26. Section “Director Compensation”. As printed: 170,423. View filing ↗
- Section 08, Sara L. Zaknoen, M.D. DEF 14A, filed 2026-03-26. Section “Director Compensation”. As printed: 167,422. View filing ↗
- Section 08, Eric Benevich. DEF 14A, filed 2026-03-26. Section “Director Compensation”. As printed: 163,849. View filing ↗
- Section 08, Paul Schimmel, Ph.D. DEF 14A, filed 2026-03-26. Section “Director Compensation”. As printed: 152,085. View filing ↗
- Section 08, John K. Clarke. DEF 14A, filed 2026-03-26. Section “Director Compensation”. As printed: 19,775. View filing ↗
- Section 08, Sanjay S. Shukla, M.D., M.S. DEF 14A, filed 2026-03-26. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Paul Schimmel 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Svetlana Lucas 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane A. Gross 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Benevich 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy P. Coughlin 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sara Zaknoen 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Schimmel 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brandon Yaras 2026-10-01. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-06. Item 5.07 · say-on-pay result. As reported: 97.61% (votes for as printed: 55,237,719). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-29. Item 5.07 · say-on-pay result. As reported: 99.07% (votes for as printed: 42,468,397). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-19. Item 5.07 · say-on-pay result. As reported: 97.37% (votes for as printed: 37,246,069). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 370,458 + equity 0 + all other 0 = 370,458, summed across the director compensation table rows.
- Scholar Rock Holding Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Scholar Rock Holding Corporation's own proxy. As printed: 33,300,927. View filing ↗
- Altimmune, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-17. CEO total compensation as printed in Altimmune, Inc.'s own proxy. As printed: 8,026,590. View filing ↗
- Allakos Inc., Section 10b CEO total. DEF 14A, filed 2024-04-23. CEO total compensation as printed in Allakos Inc.'s own proxy. As printed: 6,299,426. View filing ↗
- Pliant Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pliant Therapeutics, Inc.'s own proxy. As printed: 5,462,901. View filing ↗
- KalVista Pharmaceuticals, Inc., Section 10b CEO total. 10-KT/A, filed 2026-04-30. CEO total compensation as printed in KalVista Pharmaceuticals, Inc.'s own proxy. As printed: 5,094,999. View filing ↗
- Savara Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Savara Inc.'s own proxy. As printed: 4,845,000. View filing ↗
- Trevi Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Trevi Therapeutics, Inc.'s own proxy. As printed: 3,944,892. View filing ↗
- aTYR Pharma (subject), Section 10b CEO total. DEF 14A, filed 2026-03-26. CEO total compensation as printed in aTYR Pharma's own proxy. As printed: 3,456,253. View filing ↗
- Jasper Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-05-19. CEO total compensation as printed in Jasper Therapeutics, Inc.'s own proxy. As printed: 3,215,003. View filing ↗
- X4 Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in X4 Pharmaceuticals, Inc.'s own proxy. As printed: 2,640,569. View filing ↗
- Gossamer Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. View filing ↗
- Longboard Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Longboard Pharmaceuticals, Inc.'s own proxy. As printed: 2,053,804. View filing ↗
- Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. View filing ↗
- Kezar Life Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Kezar Life Sciences, Inc.'s own proxy. As printed: 927,300. View filing ↗
- Section 10a, Altimmune, Inc. reciprocity. DEF 14A. Altimmune, Inc. names aTYR Pharma in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Gossamer Bio, Inc. reciprocity. DEF 14A. Gossamer Bio, Inc. names aTYR Pharma in its own disclosed peer group (read from its most recent proxy). View filing ↗